ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements with these filters
Alembic Pharmaceuticals incorporated a wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in the UAE for Rs. 0.26 Crore to explore new business opportunities in pharmaceuticals.
Alembic Pharmaceuticals incorporated a wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in Dubai to explore new business opportunities and distribution.
Alembic Pharmaceuticals executed a Shareholders' Agreement to acquire a 45% stake in a new Canadian corporation. The venture focuses on pharmaceutical commercialization in Canada.
Alembic Pharmaceuticals Limited has incorporated a new wholly-owned subsidiary, Alembic Pharmaceuticals GmbH, in Germany. The company invested EUR 25,000 (₹0.27 Crore) to establish this entity, which will promote and distribute pharmaceutical products in the region.
Alembic Pharmaceuticals Limited has incorporated a wholly owned subsidiary, Alembic Pharmaceuticals GmbH, in Germany with a share capital of EUR 25,000 (₹0.27 Crore). The new entity will explore business opportunities and promote, sell, and distribute the company's pharmaceutical products in the German market.
Alembic Pharmaceuticals Limited has incorporated a new subsidiary, Alembic Lifesciences Philippines Inc., in the Philippines. The company invested ₹2.00 Crore (12 million Philippine Pesos) for a 99.99% stake to promote and distribute pharmaceutical products in the region.
Alembic Pharmaceuticals Limited incorporated a new subsidiary, Alembic Lifesciences Philippines Inc., in the Philippines. The company invested 12 million Philippine Pesos (₹1.85 Crore) for a 99.99% stake to promote and distribute pharmaceutical products in the region. This expansion marks a strategic entry into the Philippines market.
Alembic Pharmaceuticals Limited has incorporated a subsidiary, Alembic Lifesciences Philippines Inc., in the Philippines. The company holds a 99.99% stake in the new entity, which has a share capital of 12 million Philippine Pesos. The subsidiary will explore business opportunities to promote and distribute pharmaceutical products in the region.